View Older Stories View More Recent Stories

Sep 12, 2020 10:45AM Pfizer and BioNTech Propose Expansion of Pivotal COVID-19 Vaccine Trial
Sep 9, 2020 07:45AM Pfizer (PFE) and BioNTech (BNTX) Announce Data From Preclinical Studies of mRNA-Based Vaccine Candidate Against COVID-19
Sep 9, 2020 07:45AM Pfizer and BioNTech Announce Data from Preclinical Studies of mRNA-based Vaccine Candidate Against COVID-19
Sep 9, 2020 07:45AM Pfizer and BioNTech Announce Data From Preclinical Studies of mRNA-Based Vaccine Candidate Against COVID-19
Sep 9, 2020 06:19AM Pfizer (PFE), BioNTech (BNTX) Announces Potential Supply to EU with 200M Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2
Sep 9, 2020 06:15AM Pfizer and BioNTech to Potentially Supply the EU with 200 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2
Sep 9, 2020 06:15AM Pfizer and BioNTech to Potentially Supply the EU with 200 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2
Sep 9, 2020 06:15AM Pfizer and BioNTech to Potentially Supply the EU with 200 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2
Sep 8, 2020 06:31AM Vaccine makers announce pledge, outlining united commitment to uphold integrity of scientific process
Sep 8, 2020 06:31AM Biopharma Leaders Unite to Stand With Science
Sep 8, 2020 06:30AM Biopharma Leaders Unite to Stand with Science
Sep 8, 2020 06:30AM Biopharma Leaders Unite To Stand With Science
Sep 8, 2020 06:30AM Biopharma Leaders Unite to Stand with Science
Sep 8, 2020 06:30AM Biopharma Leaders Unite to Stand with Science
Aug 21, 2020 06:05AM Pfizer (PFE), BioNTech (BNTX) Share Positive Early Data on Lead mRNA Vaccine Candidate BNT162b2 Against COVID-19
Aug 20, 2020 08:16PM Pfizer and BioNTech Share Positive Early Data on Lead mRNA Vaccine Candidate BNT162b2 Against COVID-19
Aug 20, 2020 08:16PM Pfizer and BioNTech Share Positive Early Data on Lead mRNA Vaccine Candidate BNT162b2 Against COVID-19
Aug 20, 2020 08:00PM Pfizer and BioNTech Share Positive Early Data on Lead mRNA Vaccine Candidate BNT162b2 Against COVID-19
Aug 5, 2020 08:02AM Pfizer (PFE) and BioNTech (BNTX) to Supply Canada with their BNT162 mRNA-Based Vaccine Candidate
Aug 5, 2020 08:00AM Pfizer and BioNTech to Supply Canada with their BNT162 mRNA-Based Vaccine Candidate
Jul 31, 2020 06:12AM Pfizer (PFE), BioNTech (BNTX) to Supply Japan with 120 Million Doses of Their BNT162 mRNA-Based Vaccine Candidate
Jul 31, 2020 05:15AM Pfizer and BioNTech to Supply Japan with 120 Million Doses of Their BNT162 mRNA-Based Vaccine Candidate
Jul 31, 2020 05:15AM Pfizer and BioNTech to Supply Japan with 120 Million Doses of their BNT162 mRNA-based Vaccine Candidate
Jul 31, 2020 05:15AM Pfizer and BioNTech to Supply Japan with 120 Million Doses of Their BNT162 mRNA-Based Vaccine Candidate
Jul 27, 2020 05:16PM Pfizer (PFE), BioNTech (BNTX) Choose Lead mRNA Vaccine Candidate Against COVID-19, Commence Pivotal Phase 2/3 Global Study
Jul 27, 2020 05:16PM Pfizer (PFE) and BioNTech (BNTX) Choose Lead mRNA Vaccine Candidate Against COVID-19 and Commence Pivotal Phase 2/3 Global Study
Jul 27, 2020 05:15PM Pfizer and BioNTech Choose Lead mRNA Vaccine Candidate Against COVID-19 and Commence Pivotal Phase 2/3 Global Study
Jul 27, 2020 05:15PM Pfizer and BioNTech Choose Lead mRNA Vaccine Candidate Against COVID-19 and Commence Pivotal Phase 2/3 Global Study
Jul 27, 2020 05:15PM Pfizer and BioNTech Choose Lead mRNA Vaccine Candidate Against COVID-19 and Commence Pivotal Phase 2/3 Global Study
Jul 22, 2020 07:11AM Pfizer (PFE) and BioNTech (BNTX) Announce Agreement with U. S. Government for up to 600 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2
Jul 22, 2020 07:10AM Pfizer and BioNTech Announce an Agreement with U. S. Government for up to 600 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2
Jul 22, 2020 07:10AM Pfizer and BioNTech Announce an Agreement with U.S. Government for up to 600 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2
Jul 22, 2020 07:10AM Pfizer and BioNTech Announce an Agreement with U. S. Government for up to 600 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2
Jul 20, 2020 08:46AM Pfizer (PFE), BioNTech SE (BNTX) Announce Early Positive Update from German Phase 1/2 COVID-19 Vaccine Study
Jul 20, 2020 08:45AM Pfizer and BioNTech Announce Early Positive Update from German Phase 1/2 COVID-19 Vaccine Study, Including First T Cell Response Data
Jul 20, 2020 08:45AM Pfizer and BioNTech Announce Early Positive Update from German Phase 1/2 COVID-19 Vaccine Study, Including First T Cell Response Data
Jul 20, 2020 06:00AM Pfizer (PFE), BioNTech SE (BNTX) Report Agreement with the U.K. for 30M Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2
Jul 20, 2020 01:00AM Pfizer and BioNTech Announce Agreement with the United Kingdom for 30 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2
Jul 20, 2020 01:00AM Pfizer and BioNTech Announce Agreement with the United Kingdom for 30 Million Doses of mRNA-based Vaccine Candidate against SARS-CoV-2
Jul 20, 2020 01:00AM Pfizer and BioNTech Announce Agreement with the United Kingdom for 30 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2
Jul 13, 2020 06:46AM Pfizer (PFE), BioNTech SE (BNTX) Granted FDA Fast Track Designation for Two Investigational mRNA-based Vaccine Candidates Against COVID-19
Jul 13, 2020 06:45AM Pfizer and BioNTech Granted FDA Fast Track Designation for Two Investigational mRNA-based Vaccine Candidates Against SARS-CoV-2
Jul 13, 2020 06:45AM Pfizer and BioNTech Granted FDA Fast Track Designation for Two Investigational mRNA-based Vaccine Candidates Against SARS-CoV-2
Jul 1, 2020 09:01AM Pfizer and BioNTech Announce Early Positive Data from an Ongoing Phase 1/2 Study of mRNA-based Vaccine Candidate Against SARS-CoV-2
Jul 1, 2020 09:00AM Pfizer (PFE) and BioNTech (BNTX) Confirms Early Positive Data from an Ongoing Phase 1/2 COVID-19 Trial
Jul 1, 2020 08:59AM Pfizer and BioNTech Announce Early Positive Data from an Ongoing Phase 1/2 study of mRNA-based Vaccine Candidate Against SARS-CoV-2
Jun 10, 2020 06:04AM Genmab (GMAB) and AbbVie (ABBV) Announce Broad Oncology Collaboration, Genmab to Receive Upfront Payment of $750M With Total Potential Milestones of Up to $3.15B
Jun 10, 2020 06:00AM Genmab and AbbVie Announce Broad Oncology Collaboration
Jun 4, 2020 07:00AM Immatics Appoints Cedrik Britten as Chief Medical Officer
May 5, 2020 06:45AM Pfizer (PFE), BioNTech (BNTX) Dose First Participants in U.S. as Part of Global COVID-19 mRNA Vaccine Development Program
View More Recent Stories View Older Stories